Pharmaceutical compositions of Anti-IGF-1r antibodies
A stable formulation of anti-IGF-1R antibodies with a specific pH range and stabilizing agents addresses the challenges of antibody stability and efficacy in treating thyroid-associated ophthalmopathy, enhancing treatment outcomes by maintaining antibody stability and modulating IGF-1R activity.
Patent Information
- Application Number
- US18/827383
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- Priority Date
- 2024-08-30
- Filing Date
- 2024-09-06
- Publication Date
- 2025-03-27
AI Technical Summary
Current therapies for thyroid-associated ophthalmopathy (TAO) are inadequate due to the lack of targeted treatments for its underlying autoimmune mechanisms, and existing antibody formulations face challenges in maintaining stability and efficacy, particularly at high concentrations.
A stable formulation of anti-insulin-like growth factor 1 receptor (IGF-1R) antibodies is developed, optimized for intravenous and subcutaneous administration, with a specific pH range of 4.8-6.5 that ensures conformational and colloidal stability, allowing for high concentration and long-term stability, comprising specific heavy and light chain variable regions and stabilizing agents like sucrose and methionine.
The formulation provides safer and more efficacious clinical use by maintaining antibody stability and purity, reducing high molecular weight species, and improving treatment outcomes for TAO by modulating IGF-1R activity.